DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma

Candace J. Poole, Wenli Zheng, Atul Lodh, Aleksey Yevtodiyenko, Daniel Liefwalker, Honglin Li, Dean W. Felsher, Jan van Riggelen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aberrant DNA methylation is a hallmark of cancer. However, our understanding of how tumor cell-specific DNA methylation patterns are established and maintained is limited. Here, we report that in T-cell acute lymphoblastic leukemia (T-ALL) and Burkitt's lymphoma the MYC oncogene causes overexpression of DNA methyltransferase (DNMT) 1 and 3B, which contributes to tumor maintenance. By utilizing a tetracycline-regulated MYC transgene in a mouse T-ALL (EμSRa-tTA;tet-o- MYC) and human Burkitt's lymphoma (P493-6) model, we demonstrated that DNMT1 and DNMT3B expression depend on high MYC levels, and that their transcription decreased upon MYC-inactivation. Chromatin immunoprecipitation indicated that MYC binds to the DNMT1 and DNMT3B promoters, implicating a direct transcriptional regulation. Hence, shRNA-mediated knock-down of endogenous MYC in human T-ALL and Burkitt's lymphoma cell lines, downregulated DNMT3B expression. Knock-down and pharmacologic inhibition of DNMT3B in T-ALL reduced cell proliferation associated with genome-wide changes in DNA methylation, indicating a tumor promoter function during tumor maintenance. We provide novel evidence that MYC directly deregulates the expression of both de novo and maintenance DNMTs, showing that MYC controls DNA methylation in a genome-wide fashion. Our finding that a coordinated interplay between the components of the DNA methylating machinery contributes to MYCdriven tumor maintenance highlights the potential of specific DNMTs for targeted therapies.

Original languageEnglish (US)
Pages (from-to)76898-76920
Number of pages23
JournalOncotarget
Volume8
Issue number44
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Burkitt Lymphoma
DNA Methylation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Maintenance
T-Lymphocytes
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
Genome
Chromatin Immunoprecipitation
Tetracycline
Transgenes
Oncogenes
Carcinogens
Small Interfering RNA
Down-Regulation
Cell Proliferation
Cell Line
DNA

Keywords

  • DNA methylation
  • DNMT3B
  • Leukemia/lymphoma
  • MYC

ASJC Scopus subject areas

  • Oncology

Cite this

DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. / Poole, Candace J.; Zheng, Wenli; Lodh, Atul; Yevtodiyenko, Aleksey; Liefwalker, Daniel; Li, Honglin; Felsher, Dean W.; van Riggelen, Jan.

In: Oncotarget, Vol. 8, No. 44, 01.01.2017, p. 76898-76920.

Research output: Contribution to journalArticle

Poole, CJ, Zheng, W, Lodh, A, Yevtodiyenko, A, Liefwalker, D, Li, H, Felsher, DW & van Riggelen, J 2017, 'DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma', Oncotarget, vol. 8, no. 44, pp. 76898-76920. https://doi.org/10.18632/oncotarget.20176
Poole, Candace J. ; Zheng, Wenli ; Lodh, Atul ; Yevtodiyenko, Aleksey ; Liefwalker, Daniel ; Li, Honglin ; Felsher, Dean W. ; van Riggelen, Jan. / DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 44. pp. 76898-76920.
@article{17378039a2ec4effa4905f72263fda66,
title = "DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma",
abstract = "Aberrant DNA methylation is a hallmark of cancer. However, our understanding of how tumor cell-specific DNA methylation patterns are established and maintained is limited. Here, we report that in T-cell acute lymphoblastic leukemia (T-ALL) and Burkitt's lymphoma the MYC oncogene causes overexpression of DNA methyltransferase (DNMT) 1 and 3B, which contributes to tumor maintenance. By utilizing a tetracycline-regulated MYC transgene in a mouse T-ALL (EμSRa-tTA;tet-o- MYC) and human Burkitt's lymphoma (P493-6) model, we demonstrated that DNMT1 and DNMT3B expression depend on high MYC levels, and that their transcription decreased upon MYC-inactivation. Chromatin immunoprecipitation indicated that MYC binds to the DNMT1 and DNMT3B promoters, implicating a direct transcriptional regulation. Hence, shRNA-mediated knock-down of endogenous MYC in human T-ALL and Burkitt's lymphoma cell lines, downregulated DNMT3B expression. Knock-down and pharmacologic inhibition of DNMT3B in T-ALL reduced cell proliferation associated with genome-wide changes in DNA methylation, indicating a tumor promoter function during tumor maintenance. We provide novel evidence that MYC directly deregulates the expression of both de novo and maintenance DNMTs, showing that MYC controls DNA methylation in a genome-wide fashion. Our finding that a coordinated interplay between the components of the DNA methylating machinery contributes to MYCdriven tumor maintenance highlights the potential of specific DNMTs for targeted therapies.",
keywords = "DNA methylation, DNMT3B, Leukemia/lymphoma, MYC",
author = "Poole, {Candace J.} and Wenli Zheng and Atul Lodh and Aleksey Yevtodiyenko and Daniel Liefwalker and Honglin Li and Felsher, {Dean W.} and {van Riggelen}, Jan",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20176",
language = "English (US)",
volume = "8",
pages = "76898--76920",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "44",

}

TY - JOUR

T1 - DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma

AU - Poole, Candace J.

AU - Zheng, Wenli

AU - Lodh, Atul

AU - Yevtodiyenko, Aleksey

AU - Liefwalker, Daniel

AU - Li, Honglin

AU - Felsher, Dean W.

AU - van Riggelen, Jan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aberrant DNA methylation is a hallmark of cancer. However, our understanding of how tumor cell-specific DNA methylation patterns are established and maintained is limited. Here, we report that in T-cell acute lymphoblastic leukemia (T-ALL) and Burkitt's lymphoma the MYC oncogene causes overexpression of DNA methyltransferase (DNMT) 1 and 3B, which contributes to tumor maintenance. By utilizing a tetracycline-regulated MYC transgene in a mouse T-ALL (EμSRa-tTA;tet-o- MYC) and human Burkitt's lymphoma (P493-6) model, we demonstrated that DNMT1 and DNMT3B expression depend on high MYC levels, and that their transcription decreased upon MYC-inactivation. Chromatin immunoprecipitation indicated that MYC binds to the DNMT1 and DNMT3B promoters, implicating a direct transcriptional regulation. Hence, shRNA-mediated knock-down of endogenous MYC in human T-ALL and Burkitt's lymphoma cell lines, downregulated DNMT3B expression. Knock-down and pharmacologic inhibition of DNMT3B in T-ALL reduced cell proliferation associated with genome-wide changes in DNA methylation, indicating a tumor promoter function during tumor maintenance. We provide novel evidence that MYC directly deregulates the expression of both de novo and maintenance DNMTs, showing that MYC controls DNA methylation in a genome-wide fashion. Our finding that a coordinated interplay between the components of the DNA methylating machinery contributes to MYCdriven tumor maintenance highlights the potential of specific DNMTs for targeted therapies.

AB - Aberrant DNA methylation is a hallmark of cancer. However, our understanding of how tumor cell-specific DNA methylation patterns are established and maintained is limited. Here, we report that in T-cell acute lymphoblastic leukemia (T-ALL) and Burkitt's lymphoma the MYC oncogene causes overexpression of DNA methyltransferase (DNMT) 1 and 3B, which contributes to tumor maintenance. By utilizing a tetracycline-regulated MYC transgene in a mouse T-ALL (EμSRa-tTA;tet-o- MYC) and human Burkitt's lymphoma (P493-6) model, we demonstrated that DNMT1 and DNMT3B expression depend on high MYC levels, and that their transcription decreased upon MYC-inactivation. Chromatin immunoprecipitation indicated that MYC binds to the DNMT1 and DNMT3B promoters, implicating a direct transcriptional regulation. Hence, shRNA-mediated knock-down of endogenous MYC in human T-ALL and Burkitt's lymphoma cell lines, downregulated DNMT3B expression. Knock-down and pharmacologic inhibition of DNMT3B in T-ALL reduced cell proliferation associated with genome-wide changes in DNA methylation, indicating a tumor promoter function during tumor maintenance. We provide novel evidence that MYC directly deregulates the expression of both de novo and maintenance DNMTs, showing that MYC controls DNA methylation in a genome-wide fashion. Our finding that a coordinated interplay between the components of the DNA methylating machinery contributes to MYCdriven tumor maintenance highlights the potential of specific DNMTs for targeted therapies.

KW - DNA methylation

KW - DNMT3B

KW - Leukemia/lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=85030324787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030324787&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20176

DO - 10.18632/oncotarget.20176

M3 - Article

VL - 8

SP - 76898

EP - 76920

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -